A lot of effort has been done to study how cancer cells react to low-oxygen tension, a condition known as hypoxia. Indeed, abnormal and dysfunctional blood vessels in the tumor are incapable to restore oxygenation, therefore perpetuating hypoxia, which, in turn, will fuel tumor progression, metastasis and resistance to antitumor therapies. Nevertheless, how stromal components including blood and lymphatic endothelial cells, pericytes and fibroblasts, as well as hematopoietic cells, respond to low-oxygen tension in comparison with their normoxic counterparts has been a matter of investigation in the last few years only and, to date, this field of research remains poorly understood. In general, opposing phenotypes can arise from the same stromal component when embedded in different tumor microenvironments, and, vice versa, different stromal components can have opposite reaction to the same tumor microenvironment. In this article, we will discuss the emerging link between tumor stroma and hypoxia, and how this complexity is translated at the molecular level.
INTRODUCTION
Oxygen tension within a tumor fluctuates from almost anoxic conditions (barely no oxygen) to 60 mm Hg (that is, 8% oxygen), depending on the tumor type. Yet, most of the tumor cells are exposed to oxygen tensions that vary from anoxia to 7.5 mm Hg (that is, 1% oxygen), a condition known as hypoxia. 1, 2 The level of hypoxia within a tumor increases during tumor progression and is a good indicator of disease outcome because hypoxia selects the most invasive cancer cells and promotes resistance to therapies. 3 A lot of attention has previously been paid on how cancer cells react to hypoxia and how low-oxygen tension contributes to malignancy (reviewed by De Bock et al. 4 ). However, the contribution of the tumor stroma in this process has never been globally reviewed. Here, we will offer a comprehensive overview on how each stromal component in the tumor, namely blood and lymphatic endothelial cells (ECs), pericytes, fibroblasts and hematopoietic cells, respond autonomously, thus independently of cancer cell reactions, to oxygen shortage. We will explain the mechanisms underlying this response and speculate some molecular links that are still missing in the field. Finally, we will underline how the contribution of hypoxia on the stroma does not always translate in pro-tumoral effects, thus highlighting the need to target individual effectors of the hypoxia response in cancer therapy.
ENDOTHELIAL CELLS
Oxygen and nutrients are delivered to the tissues by a complex vascular network in our body. As diffusion of oxygen is limited to about 100-200 mM, rapidly growing tumors need new blood vessels to be able to grow beyond this size. 5 In contrast to the physiologically normal vasculature, tumor vessels are abnormal owing to excessive production of angiogenic factors by the tumor in response to lack of oxygen, therefore initiating a vicious cycle where oxygenation is never restored within the tumor. 5, 6 The tumor endothelium lacks instead tight connections, shows excessive sprouting, is not covered by supporting mural cells and shows a highly irregular basement membrane. 5, 6 These characteristics lead to a dysfunctional, leaky vasculature, thereby increasing intratumoral pressure and limiting the diffusion of oxygen, nutrients and anticancer drugs. [5] [6] [7] Over the past years, it became clear that tumors harbor a myriad of ways to build their own vascular network. 8 Most of the EC reactions to hypoxia are indirectly caused by the response of cancer cells or a different stromal cell, which release angiogenic factors when oxygen tension decreases. Although counterintuitive because of the intrinsic function of blood vessels to deliver oxygen, ECs themselves can become hypoxic. 6, 9, 10 During pathological events such as tumor growth, metastasis or ischemia, 6, 11, 12 but also in veins that are filled with poorly oxygenated blood and probably in sprouting vessels where the perfusion is not complete yet, 13, 14 hypoxic ECs mount adaptive responses to restore tissue oxygenation ( Figure 1 ).
As all other cells, ECs express three isoforms of prolylhydroxylase enzymes (PHD1, PHD2 and PHD3) and the factorinhibiting HIF1 (FIH1), which control the protein levels of the hypoxia-inducible factors HIF1 and HIF2. Under normoxic condition, the alpha subunit of HIF is hydroxylated at prolyl and asparagine residues by PHDs and FIH, respectively, thus leading to HIF degradation in the first case or to HIF inactivation in the latter (reviewed by Fraisl et al. 15 ). A drop in oxygen tension reduces PHD and FIH1 activity and stabilizes/activates HIF1a and HIF2a, which initiate a transcriptional response. 16 In ECs, HIF1a only is fully stabilized at very low-oxygen tensions that are close to anoxia, 17 whereas HIF2a can even activate transcription in cooperation with the ETS (E-twenty six) family transcription factors in normoxia. 18, 19 These results, together with the fact that EC-specific deletion of HIF2a in adult mice causes vascular disruption and permeability, suggest that HIF2a is required to preserve a stable, quiescent vasculature, likely also when tissue oxygenation is restored back to the normal level. 6, 20 Consistently, EC-specific deletion of HIF2a results in increased angiogenesis in cancer and ischemia; however, the neoformed vasculature is immature and poorly functional, providing evidence that HIF2a has an inhibitory effect on vessel sprouting, while promoting vessel maturation. 12, 20 In contrast, HIF1a is more important in hypoxia when angiogenesis is necessary to restore tissue oxygenation. In cancer, EC-specific deletion of HIF1a results in loss of the angiogenic potential, with reduced EC proliferation and migration. 21 These opposing functions of HIF1a and HIF2a in the endothelium can be explained by evaluating their panel of nonredundant downstream targets. Hypoxic cells release vascular endothelial growth factor (VEGF), which reaches the nearest existing vasculature. 22 The EC that senses the highest VEGF concentration, and consequently impinges on the highest VEGF receptor (VEGFR)2 signaling, will extend filopodia to migrate toward VEGF and will become the 'tip cell'. 22 VEGF-mediated VEGFR2 signals will induce Delta-like ligand 4 (DLL4) on the surface of tip cells. However, as the tip cell is moving toward the hypoxic area, PHDs and FIH are also inactivated, favoring HIF1 and/or HIF2 accumulation. Likely, HIF1a will be stabilized, as it is required for migration and invasion and is able to induce VEGF and VEGFR2, further maintaining the tip-cell phenotype. 12, 21 Binding of DLL4 from the tip cell to NOTCH2 expressed by the adjacent ECs prevents these cells to become tip cells. 23 Instead, these cells will become 'stalk cells', that trail behind the tip cell, allowing elongation of the new sprout by extensive proliferation.
At this stage, lumen formation has not occurred yet, and flow is not present; thus, these cells are most probably hypoxic, although less severely than at the tip position. However, how this affects HIF signaling remains unclear. Literature evidence supporting the proliferative function of HIF1a and the maturation function of HIF2a would suggest that both factors are stabilized. 12 VEGF signaling triggered by HIF1 is then weakened by HIF2-and/or NOTCH2-mediated transcription of VEGFR1-and NOTCH2-mediated suppression of VEGFR2. 6, 11, 24 In a dynamic process, this final event will lead toward a mature quiescent vasculature, where ECs acquire a 'phalanx cell' phenotype, favored by HIF2a accumulation, with the consequent transcription of VEGFR1 and VE-cadherin, further reducing VEGFR2 signaling and tightening the endothelial barrier. 6 As suggested above, this step might start in hypoxia but perpetuated at a higher oxygen tension, as HIF2a mediates VE-cadherin and VEGFR1 transcription in normoxic conditions as well. 18, 19 Thus, the balance between VEGFR1 and VEGFR2 is important to define the endothelial cell phenotype and is highly regulated by NOTCH signaling. 24 Less clear is the role of HIF1a and HIF2a in these processes, although suggestive findings highlight the relevance of these two transcription factors in EC phenotype determination. 12, 20, 21 The different affinities of PHDs versus FIH1 for oxygen (Km ¼ 100-250 mM for PHDs; Km ¼ 90 mM for FIH) suggest that FIH1 inactivation might be instrumental in anoxia, thus in the migratory, non-perfused tip cell, whereas PHD inactivation might have a more relevant role during mild changes in oxygen tension as it likely occurs along the vessel stalk. In favor of this idea, FIH1 mainly controls HIF1a and minimally hydroxylates HIF2a 25 Thus, full HIF1a activity can be restricted to those ECs that are present in more severe hypoxic/anoxic tumor areas, which are the migratory tip cells. Conversely, hypoxic inactivation of PHD2 regulates the maturation and stabilization of the new vessel sprout. 6 Likewise, EC deletion of PHD2 results in preferential HIF2-mediated transcription of VE-cadherin and VEGFR1, leading to tumor endothelial normalization with improved vessel perfusion as a consequence. 6 A reduction of PHD2 activity by hypoxia in wildtype ECs will also trigger this HIF2-mediated vessel reshaping, but less efficiently than genetic loss of PHD2. In other words, hypoxic inactivation of PHD2 in wild-type ECs cannot overcome the strong abnormalization response by cancer cells. Conversely, gene depletion of PHD2 adapts the endothelium to hypoxia and counters the excessive release of angiogenic factors by cancer cells, which results in a normalized vasculature. [5] [6] [7] PHDs, FIH1 and HIFs in ECs can also be regulated by other factors such as FGF and EGF, which are able to stabilize HIF2. 18 However, how cytokinemediated HIF regulation affects EC behavior is unknown, leaving many opportunities open in this research field.
Genetic studies on HIF in ECs provide some insights for clinical intervention in cancer biology. EC-specific deletion of either HIF1a or HIF2a inhibits tumor growth; however, metastases were reduced only in mice lacking endothelial HIF1a, whereas they were increased upon loss of endothelial HIF2a. 20, 21, 26 These opposite observations on metastasis were in part ascribed to the inverse functions of EC-borne HIF1 and HIF2 on nitric oxide (NO) metabolism, and thus vessel permeability and cancer cell migration toward other organs. 20, 21, 26 A remaining important question is how and whether hypoxic stress (or other factors) can cause differential induction of the two HIF isoforms in the ECs of pre-metastatic organs. To complement these findings, our work has shown also that HIF2 stabilization upon gene targeting of PHD2 inhibits cancer cell intravasation and improves delivery of chemotherapeutics because of reduced vessel permeability and hypoxia, but increased perfusion. However, both HIF1 and HIF2 were required to promote a detoxification program in healthy organ and prevent the side effects of chemotherapy. 7 Overall, this study warrants some caution for considerate use of HIF blockers in cancer therapy in association with chemotherapy, as this was previously suggested on the basis of some protective role of HIFs against cancer cell death. 4 Conversely, PHD2 blockers might be preferred.
LYMPHATIC ENDOTHELIAL CELLS
Lymphangiogenesis and lymph node invasion by cancer cells impact heavily on cancer prognosis. Lymph vessels represent a possible route for systemic dissemination of cancer cells and their presence in the tumor and in the peritumoral areas correlates with a bad outcome in different cancer types, such as breast cancer and melanoma; 27 axillary lymph node metastasis represents an important risk factor for distant metastasis and poor outcome of breast cancer. 28 Similarly to what happens with tumor blood vessels, cancer cells can trigger lymphangiogenesis according to their needs, and their responses to hypoxia favor this process ( Figure 1) . Indeed, medium conditioned by hypoxic breast cancer cells induces motility and proliferation of lymphatic endothelial cells (LECs). 29 Moreover, HIF1a levels correlate with VEGF-C expression and lymphangiogenesis in breast cancer, 30 mesothelioma 31 and oral squamous cell carcinoma. 32 This hypoxia-driven lymphangiogenesis could represent a 'smart' way for cancer cells to escape from an environment with low-oxygen tension and nutrients to reach a more vascularized place.
Gene expression analysis by independent investigators revealed that exposure of LECs to low-oxygen concentrations induces HIF1a, HIF2a, VEGF-A, VEGF-C, VEGF-D, adrenomedulin, ceruloplasmin, the glucose transporter GLUT-1 and the glycolytic enzyme, glyceraldehyde phosphate dehydrogenase. 33, 34 Thus, in hypoxia, LECs display a delayed proliferation, increased adhesion to extracellular matrix proteins, augmented glycolytic flux and reactive oxygen species (ROS) detoxification, and pro-angiogenic features. Hypoxia induces also CXCR4 expression in cancer cells and LECs, which also release higher amounts of its ligand CXCL12 (also known as SDF1), thus favoring the attraction and adhesion of cancer cells to the lymphatic endothelium. 34 Another study reports that hypoxia induces NOTCH signaling resulting in VEGFR2 downregulation in LECs and reduction of their migration. 35 Despite these in vitro findings, whether lymphatics are exposed to hypoxia within the tumor and how they respond to this condition in vivo has been poorly characterized. We can speculate that, as lymphatics emerge from the poorly oxygenated venous system in response to NOTCH-mediated signals, 36 LECs have to be able to migrate and form lymph vessels in a hypoxic tissue and might be genetically and metabolically preadapted to this condition. Hangai-Hoger et al. 37 show that oxygen tension inside the lymphatic vessels is lower than that in the outer perivascular tissue, but this was because of oxygen consumption by LECs and lymphocytes. On top of this, LECs at the forefront of the new sprout extend long filopodia and lamellipodia to migrate, that are a reminiscence of endothelial tip cells in blood vessels, whereas LECs trailing behind the tip cell can be phenotypically associated to proliferating stalk cells. 36 Likewise, DLL4/NOTCH signaling has been implicated in this process, both in vitro and in vivo. 36 It remains unknown whether and how oxygen affects the balance between tip versus stalk LECs, and whether hypoxia or alternatively PHD2 inactivation gives rise to more quiescent, sessile, non-proliferative 'phalanx LECs' in vivo, as this occurs for blood vessels.
PERICYTES
Pericytes are perivascular cells that stabilize the vasculature. In physiological conditions mature blood vessels are quiescent with a well-organized structure and ECs are well aligned and tightly connected to each other and covered by pericytes, which are recruited through the release of platelet-derived growth factor-B (PDGFB) by ECs themselves. In turn, VEGF and angiopoietin-1, secreted by pericytes, induce survival and stabilization of ECs in mature vessels. 5 During cancer pathologies, hypoxia and proangiogenic signals from the tumor microenvironment modify the interaction between pericytes and ECs, therefore compromising the structure and hierarchy of mature vessels ( Figure 1 ). In these conditions, pericytes establish loosely or no association with the ECs, resulting in immature tumor vessels. 5 Mechanistically, HIF1 accumulation in pericytes leads to the transcriptional upregulation and release of VEGF and angiopoietin-2. 38 Also, the ligand tumor necrosis factor-like weak inducer of apoptosis, which in ECs induces migration and proliferation, 39, 40 accumulates in response to hypoxia in pericytes, and induces the upregulation of matrix metallopeptidase 9 through nuclear factor-kB activation. 38 Hypoxia-induced angiopoietin-2 competes with angiopoietin-1 for the binding to the angiopoietin-receptor TIE2. Thus, pericytes detach from the endothelium, leading to vessel destabilization that allows VEGF-driven remodeling and sprouting. 38, 41 Consistently, the combination of VEGF receptor and PDGFB receptor inhibitors affect pericyte-mediated EC survival, resulting in tumor blood vessel regression and tumor growth inhibition. 42 However, genetic or pharmacological pericyte depletion has an important caveat, as the consequent hypoxia and vascular leakage that are generated following these treatments lead to the upregulation of pro-metastatic genes and, in particular of the tyrosine kinase receptor c-MET, ultimately fueling distant dissemination in spontaneous and orthotopic mammary tumor models. 43 Thus, in some tumors, pericyte targeting, alone or in combination with antiangiogenic treatments, inhibits tumor growth, blood vessels, lymph vessels and metastasis. In some others, reduced microvessel density and stability following pericyte depletion leads to severe hypoxia that will foster the invasive behavior of cancer cells, and a more leaky vasculature will also allow cancer cells to squeeze through the discontinued vessel wall. 42, 44, 45 A better strategy to reduce vessel sprouting as well as 
CANCER-ASSOCIATED FIBROBLASTS
Cancer-associated fibroblasts (CAFs) represent one of the most preponderant stromal populations in many tumor types. 48 Compared with the normal fibroblasts, CAFs overexpress a set of distinctive markers associated with malignant features, including the PDGF receptors and the membrane-bound gelatinase fibroblast activation protein. 49, 50 In general, CAFs favor tumor progression and cancer cell dissemination by remodeling the extracellular matrix and by releasing pro-tumoral chemokines and growth factors, which promote tumor angiogenesis and inflammation. 51 CAFs originate from different cell populations: bone-marrow mesenchymal stem cells, 52 resident fibroblasts, 53 cancer cells (following epithelial to mesenchymal transition) or ECs (following endothelial to mesenchymal transition). 54, 55 Despite the molecular mechanism underlying the promotion of the CAF phenotype is not completely known, the relevance of some hypoxia-modulated genes in determining this cell fate has been previously described (Figure 2 ). For example, intratumoral hypoxia promotes a selective Caveolin-1 downregulation in fibroblasts by lysosomal degradation, 56 and loss of Caveolin-1 by gene deletion in mammary fibroblasts induces a CAF-like phenotype. Accordingly, overexpression of the hypoxia-regulated HIF1a in human mammary fibroblasts downregulates Caveolin-1 and fuels tumor growth and metastasis when coinjected together with breast cancer cells in nude mice. 57 Compared with normal fibroblasts, CAFs isolated from breast tumors showed a significant reduction of Caveolin-1 in most, but not all cases, 58, 59 and this reduction was associated with a poor clinical outcome. 58 On the other hand, constitutive deletion of HIF1a in fibroblasts before tumor onset accelerates tumorigenesis by attenuating macrophage infiltration and improving blood perfusion, although the molecular players underlying these processes were not described. 60 This apparent contradiction can be due to the fact that fibroblast-borne HIF1a might suppress cancer at early stages, whereas it could turn into an oncogene later during progression, or simply fibroblast-borne HIF1a can have opposing roles in different cancer types. It is possible that these two opposing functions of HIF1a in CAFs with respect to the growth of primary tumors are instead in agreement when looking at the effect of CAF-borne HIF1a on metastasis. Indeed, although Chiavarina et al. 57 showed a pro-metastatic effect by HIF1a overexpression in CAFs, the study of Kim et al. 60 suggests that fibroblast-borne HIF1a is, at least in part, responsible for tumor vessel dysfunction, hypoperfusion and increased tumor hypoxia, which correlates with a higher risk to develop metastasis, independently of tumor size.
A different study showed that genetic deletion of JunD in the stroma promotes tumor growth and metastasis by fibroblast activation. Mechanistically, loss of JunD in fibroblasts increases ROS production, with consequent inactivation of PHDs, accumulation of HIF1a and thus HIF1a-dependent induction of CXCL12. The signaling induced by CXCL12 through its receptor CXCR4 activates fibroblasts, promoting CAF differentiation and their malignant phenotype. 61 Furthermore, hypoxia-induced transforming growth factor-b by cancer cells, alone or in combination with an autocrine loop of CXCL12, drives CAF differentiation toward the tumorpromoting phenotype later during progression. 62, 63 Although this evidence supports the idea that hypoxia prompts normal fibroblasts to acquire the CAF phenotype (but not necessarily their malignancy), it is still unknown whether this represents a 'conditio sine qua non'; therefore, if hypoxia is indispensable and sufficient for this process. Until now, CAFs are mainly described as tumor promoters and for this reason they have been targeted for therapeutic purposes. Nevertheless, therapies aiming to block CAFs by using antifibroblast activation protein antibodies do not show great results in clinical trials. 49 This could be ascribed to the fact that CAFs can have opposing roles in different cancer types, or probably that different stromal components can take over the pro-tumoral functions of CAFs, once these cells are targeted.
Further studies could help to solve still unanswered questions. In particular, we still need to define the precise CAF signature during tumor progression, how it changes in different tumor types and how it is influenced by tumor hypoxia and tumor grade.
TUMOR-INFILTRATING MYELOID CELLS
Myeloid cells are the major players of the innate immune response and they exert their functions in hypoxic areas such as wounds 64 or injured, necrotic tissues. 65 Therefore, these cells must be able to adapt to hypoxia (Figure 3 68 allowing recruitment and retention of bone marrow-derived endothelial or pericyte progenitor cells, and myeloid cells in ischemic tissues 69 or in tumors. 67, 70 Tumor-infiltrating myeloid cellss are mostly composed of neutrophils and macrophages. Neutrophils Neutrophil recruitment into human tumors occurs mainly in response to interleukin-8 (IL8), which is strongly induced by hypoxia. 71, 72 Hypoxia also induces Semaphorin 7A in ECs via HIF1, and this facilitates transendothelial migration of neutrophils into the tissue through the interaction with the receptor PlexinC1. 73 Neutrophils express PHD1, PHD2 and PHD3 as well as FIH1; 74, 75 these molecules affect neutrophil biology in hypoxic microenvironments. For example, HIF1 influences neutrophil metabolism. Neutrophils (as well as macrophages) rely on glycolysis for energy production. 76, 77 Genetic deletion of HIF1a in the myeloid cell lineage reduces adenosine triphosphate production in neutrophils and macrophages, and thus reduces their infiltration at the inflammatory site. 76 Hypoxia can also prolong neutrophil lifespan 78 through a nuclear factor-kB-dependent mechanism. HIF1 regulates the transcription and activation of nuclear factor-kB and of its positive regulator IKKa; 74 moreover, HIF1 induces PHD3 in a feedback loop, and this upregulation leads to the accumulation of the pro-survival protein BCL-X L and downmodulates the proapototic protein SIVA1, resulting in delayed neutrophil apoptosis in hypoxia, although the mechanism of regulation of these pathways by PHD3 was not investigated. 79 Hypoxia also inhibits the neutrophil respiratory burst. 80 Mechanistically, hypoxic neutrophils display reduced extracellular and intracellular ROS generation, independently of their expression of nicotinamide adenine dinucleotide phosphate oxidase components, likely because of the lack of oxygen availability. 80 As a consequence, hypoxic neutrophils are less efficient in their phagocytic activity against some bacteria.
80
To date, little is known about the influence of hypoxia on tumor neutrophils. Like all the other immune cells, neutrophils contribute to the tumor outcome in a complex way. Similar to macrophages, also neutrophils can be polarized and display different phenotypes spreading from an antitumor (N1-like) to a pro-tumor (N2-like) phenotype. 81 Indeed, neutrophils selectively kill tumor cells 82 through ROS or NO release, 81, 83, 84 Fas-mediated apoptosis, or the release of defensins and proteases, following neutrophil degranulation. 84, 85 Neutrophils can also indirectly inhibit tumor growth by promoting activation of cytotoxic T lymphocytes and by secreting proinflammatory cytokines and NO. 81 In contrast, protumoral neutrophils can foster tumor growth and invasion by releasing proteases and by promoting angiogenesis. 85 High expression of arginase, which is an important immune suppressor of the adaptive immune system, is also correlated with the N2 phenotype. 81 The neutrophil-specific serine protease elastase favors cancer cell proliferation, 86 and its release from the azurophil granules of activated neutrophils is increased under hypoxia. 80 Overall, it remains unclear whether and how hypoxia can influence neutrophil polarization. HIF1 and HIF2 seem to have opposite functions in macrophage M1/M2 polarization. [87] [88] [89] If this would be the case for neutrophils as well, specific targeting of HIF1 or HIF2 could represent a novel therapeutic approach to guide immune cell polarization in vivo.
Tumor-associated macrophages Tumor-associated macrophages (TAMs), together with CAFs, are the most represented stromal compartment. TAMs have a key role in cancer-related inflammation by several mechanisms, including stimulation of angiogenesis, tumor growth, invasion and metastasis, as well as inhibition of antitumor immune responses. 90 Interestingly, the majority of macrophages present in diseased tissues tend to accumulate in or adjacent to poorly vascularized, hypoxic sites, where considerable tissue damage may have occurred. 91 Although it appears clear how hypoxia initiates inflammation and recruits monocytes from the bloodstream (reviewed by Eltzschig and Carmeliet 92 ), much less attention has been paid on how oxygen tension shapes the inflammatory response of macrophages and modulates specific differentiation states. It has been known for long time that macrophages can be stimulated by environmental signals to exhibit a broad spectrum of phenotypes. 93 For simplicity, the two extremities of this spectrum are defined as M1 and M2 macrophages. M1 macrophages are the classically activated proinflammatory, antitumor macrophages, whereas M2 macrophages are alternatively activated, pro-angiogenic and immunosuppressive. At early stages of tumor progression, when the tumor is likely less hypoxic, TAMs exhibit an immune stimulating (M1-like) phenotype consisting of increased ability of antigen presentation, cytotoxicity and promotion of T cell-mediated antitumor immunity. 94, 95 During tumor progression and when hypoxia in the tumor increases, TAMs display defective production of inflammatory cytokines that results in decreased tumoricidal activity, and progressively they acquire pro-tumoral M2 functions driven by various cytokines and signals expressed within the tumor microenvironment. 96 The transcriptional profile of hypoxic macrophages clearly demonstrates that HIF1 and HIF2 are important factors regulating macrophage functions in hypoxia through activation of a distinct set of genes mediating unique biological functions; 97 however, the final effect of this regulation on hypoxic TAMs are not univocal. First, HIF1a positively controls inflammatory responses by promoting glycolysis and energy production in myeloid cells at the inflammatory hypoxic site. 76 As a consequence, deletion of HIF1a in myeloid cells results in reduced macrophage selfaggregation, invasion and motility. 76 Second, hypoxia-induced HIF1a in TAMs influences their localization within the tumor by selective upregulation of CXCR4 in TAMs, and increased release of CXCL12 by the hypoxic tumor. 98 Third, TAMs react to hypoxia by increased expression of HIF-mediated pro-angiogenic genes such as VEGF. 91 VEGF release by TAMs is responsible for tumor blood vessel dysfunction and abnormalities, and increased tumor hypoxia, as genetic deletion of VEGF in myeloid cells normalizes tumor vessels and restores perfusion. 99 Finally, in cancer, TAMborne HIF1a mediates the suppression of adaptive immunity as loss of HIF1a in myeloid cells directly relieves a hypoxia-induced suppression of T-cell activation in an inducible NO synthase (iNOS)-dependent manner. 100 Although these data suggest HIF1a as a good M2-like marker, proinflammatory interferon-g, an important M1-like cytokine, is strongly associated to HIF1. In fact, interferon-g elicits transcriptional induction, and thus hypoxia-independent accumulation of HIF1a 101 and, in turn, HIF1 promotes hypoxia-mediated production of interferon-g 102 Hypoxia also primes macrophages via HIF1 (and independent of any other stimulus) to secrete proinflammatory cytokines, to present antigens efficiently, and to induce phagocytic activity, suggesting a pivotal role of HIF1 hypoxia induction in preparing an active M1-like response. 102 To further support this concept, HIF1a-deficient macrophages develop a more prominent M2-like profile accompanied by decreased cytotoxicity through the reduction of NO production, 103 which is functionally associated with the cytotoxic activity of M1 macrophages against cancer cells.
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The resulting contradiction that rises from these data prompts us to contextualize the role of HIF1 in a wider scenario. During the early phase of tumor development, macrophages encountering transformed cells are M1-like, as they express iNOS and produce large quantities of NO. NO production by macrophages may promote HIF1 stabilization in an autocrine manner, inducing the production of pro-angiogenic mediators and simultaneously the production of proinflamatory and cytotoxic interferon-g. In addition, high quantities of NO induce cancer cell death. Necrotic tumor cells release immunosuppressive factors such as transforming growth factor-b and IL10, which mediate alternative M2 macrophage polarization, characterized by attenuated iNOS, but increased arginase expression. Consistently, M2-like skewing can be also induced by specific cytokines in normoxia, such as IL-4 and others, which mimic a hypoxic condition ('hypoxia-like') by inducing the upregulation of transcriptional factors other than HIF1, that is, nuclear factor-kB and/or HIF2. 101, 104, 105 However, cancer cells in hypoxia will also potently fuel the arginasedependent arm of immunosuppressive macrophages 106 that, together with HIF1-mediated induction of iNOS, promotes T cell anergy in the hypoxic microenvironment, the former by transforming L-arginine into urea and the latter using L-arginine to generate NO. In conclusion, in M2-like TAMs, L-arginine depletion and a decrease in NO production (due to a shift from iNOS toward arginase expression by hypoxia-independent mechanisms) may contribute to tumor growth by enhancing vascularization and chemoresistance of cancer cells, whereas induction of iNOS in hypoxia will promote tumor immunosuppression. 107 So far, our knowledge on the microenvironmental stimuli regulating NO functions toward pro-tumoral or antitumoral effects are only rudimentary. Understanding the intertwined relationship between NO and hypoxia/HIF1a will enable us with a therapeutic rationale to hijack this pathway in the fight of cancer. Finally, we Tumor stroma in hypoxia A Casazza et al urgently need to define the molecular cues that guide TAMs from the extravasation site to the avascular, hypoxic tumor areas, in order to be able to prevent the pro-angiogenic and immunosuppressive functions of TAMs. As such, TAMs localized into hypoxic niches could offer attractive targets for diagnostic and therapeutic application. In light of this, nanobodies against the macrophage mannose receptor, a well-characterized marker for most M2-oriented tumor promoting macrophages, have been recently developed and successfully used for efficient targeting of TAMs. 87 Moreover, Griffiths et al. 108 have presented data to indicate that macrophages can be used as silent carriers of a gene therapy until they infiltrate diseased tissue at which point they can respond to the hypoxic microenvironment and activate the expression of a therapeutic gene.
In-depth studies are still required to define the molecular pathways responsible for macrophage re-education executed in tumor hypoxic niches; this knowledge will offer new opportunities for the development of alternative cancer therapies.
Dendritic cells Dendritic cells (DCs) are professional antigen-presenting cells of both myeloid and lymphoid origin, found in several tissues and in lymphoid organs. Their function is to recognize, take up and process pathogens in the peripheral tissues and present pathogen-derived antigenic peptides in the context of major histocompatibility molecules to naive T lymphocytes in lymphoid organs. 109 During acute challenges such as infections, DCs in peripheral sites must internalize antigens and migrate to secondary lymphoid tissues to initiate immune responses. With chronic exposure to antigens such as cancer, however, DCs are bombarded with conflicting signals. The complex environment within the tumor determines the magnitude and polarity of numerous changes in DCs (Figure 3) .
Tumor-associated DCs (TA-DCs) cross-present tumor-associated antigens to recruited cytotoxic T lymphocytes. When activated, TA-DCs can mediate the sensitization of naive T cells that have been recruited into the tumor site. For this reason, interaction between tumor-infiltrating T cells and TA-DCs is essential for activating and maintaining specific antitumor immune responses. However, TA-DCs can also induce tolerance, rather than immune activation, to the tumor-associated antigens that they are presenting, depending on how DCs integrate information collected from the environment. DCs may respond actively to tolerogenic signals, such as IL10 and transforming growth factor-b, which exist in the immunosuppressive environment, by inducing regulatory T cell expansion. 109 Besides an immune 'paralysis,' there are several reports showing that TA-DCs are able to produce angiogenic factors and can promote angiogenic processes in the tumor microenvironment. 110 In general, the role of TA-DC in the establishment of antitumour immunity, or in the induction of tolerance, remains controversial and probably this sticks to the fact that the role of hypoxia in this context remains unclear. Divergent effects of hypoxia on DC maturation were reported in previous studies based on the expression of maturation markers, costimulatory molecules, chemokine receptors and T cell-priming ability. Some reports linked low-oxygen tension to promotion of DC maturation and HIF1-mediated migration 111, 112 in contrast with other data, showing that hypoxia impairs DC differentiation, adaptation and activation in inflamed tissues by limiting selfantigens uptake; hypoxia may even contribute to the failure of inducing an immune response against tumors by downmodulating the DC's ability to capture tumor antigens in the microenvironment. 113 In addition, exposure to chronic hypoxia enhances immature DC death in a HIF1-dependent manner. 113 Unraveling these apparent contradictions could help to improve DC immunotherapy, now considered still suboptimal by looking at the results of clinical trials. In fact, the hypoxic tumor microenvironment leads to massive production of VEGF, IL10 and CCL28 that together contribute to angiogenesis and promote immune tolerance greatly by recruiting immunosuppressive regulatory T cells (T regs) that limit the success of immunotherapy. 114 
TUMOR-INFILTRATING LYMPHOCYTES
Tumor-infiltrating lymphocytes are a highly heterogeneous population responsible for both pro-and antitumoral immunity. Tumor-infiltrating lymphocytes consist of cells belonging to either the innate (natural killer cells) or adaptive (T and B lymphocytes) branches of the immune system. The response of each cell type to a hypoxic environment has been described in more or less detail, and appears to have an important influence on its effector functions (Figure 3) .
B lymphocytes B cells have been extensively investigated in autoimmunity and tissue transplantation, but they are often overlooked in cancer immunology. Nevertheless, B cells do infiltrate the tumor 115, 116 and are positively correlated with patient survival. 117, 118 How they mechanistically exert an antitumor response remains mostly speculative (reviewed by Nelson 119 ). The possible effect of hypoxia on B cell functions remains largely unknown. It is particularly striking that there are no reports on the influence of hypoxia on antibody production, which is the main activity of B cells. Tumor-reactive antibodies are important for antitumor antibody-dependent cell-mediated cytotoxicity. 120 On the other hand, B cell humoral immunity can signal through Fcg receptors and skew macrophages to a M2-like, pro-angiogenic phenotype that promotes tumor progression. 95 It could be of particular interest to investigate whether hypoxia can favor the pro-or antitumoral pathway of this apparent paradoxical role for humoral immunity, by interfering with either B cell antibody production or macrophage Fcg receptors signal transduction.
The importance of hypoxia signaling during B cell development has been studied using the RAG2-deficient blastocyst complementation system to generate chimeric mice containing HIF1a-deficient B and T cells. HIF1a deficiency resulted in abnormal B1 cells (B cell subset responsible for the production of protective natural antibody) in the peritoneal cavity, 121 the development of autoimmunity and distortions in B2 cell (conventional follicular B cell subset) maturation in the bone marrow. 122, 123 This HIF1a-mediated unbalance in B cell populations could have important implications in cancer immunology as peritoneal B1 cells have been found to strongly stimulate inflammatory, antitumoral Th1 and Th17 cell development, and their differentiation in innate response activator B cells is crucial for an appropriate innate immune response, while B2 cells stimulate immunosuppressive T regs. 124, 125 On the other hand, effector B2 cells can be classified as either Be1 cells or Be2 cells, secreting cytokines of type 1 or type 2 immunity, respectively. 126 However, if hypoxia or HIF isoforms can shift the balance between Be1 and Be2 cells, and thus between anti-or pro-tumoral activity, remains unknown. This knowledge could be of particular importance when considering ex vivo manipulation of B lymphocytes before adoptive transfer. Indeed, adoptive transfer of in vitro-activated B cells mediates tumor regression; an effect that was synergic with cotransferred T cells. 120 Regardless of B cell polarization, downregulation of HIF1a activity could protect adoptively transferred B cells from cell cycle arrest in hypoxic regions of the tumor. 127 T lymphocytes T lymphocytes come in many flavors. Cytotoxic CD8 þ T cells, CD4
þ T helper cells (Th1, Th2, Th9, Th17 and Th22) and T regs
Tumor stroma in hypoxia A Casazza et al have all been described to either promote or inhibit tumor growth. Despite this plethora of phenotypes, T cell viability and cytolytic functions are strongly suppressed by hypoxia in the tumor microenvironment. [128] [129] [130] In hypoxia, the adaptor protein p66Shc is involved in HIF1a protein accumulation, which is accompanied by inhibition of proliferation and the induction of apoptosis in T cells. 131 Most probably, as a consequence of HIF1a accumulation, p66Shc induces VEGF production and turns hypoxic T cells highly angiogenic. 132 Indeed, tumor hypoxia particularly recruits immunosuppressive T regs and augments their angiogenic ability. 114 Furthermore, hypoxia-induced HIF1a upregulates the expression of the transcription factor Foxp3, and thus increases the number and suppressive properties of T regs. 133 In contradiction with these observations, Dang et al. reported a remarkable non-transcriptional role for HIF1a, which binds Foxp3 and targets it for proteasomal degradation, hereby inhibiting T reg differentiation. 134 Instead, antitumor Th17 cell development was enhanced by hypoxia-induced HIF1a through transcriptional activation of RORgt and concomitant positive regulation of Th17 signature genes. Of note, HIF1a levels can also be increased in a hypoxia-independent manner in Th17 cells. Signaling through mTOR activates a HIF1a-dependent glycolytic pathway that stimulates Th17 development and attenuates T reg differentiation. 135 A glycolytic switch in general is essential and necessary to cope with the massive bioenergetics demands of clonal expansion, following T cell antigen recognition and activation. 136, 137 Much attention goes to the role of ERK and AKT signaling pathways and to the mammalian target of rapamycin (mTOR) as metabolic regulators in this process, but more recently also HIF1a appears in the picture, which is obvious, considering the importance of its transcriptional targets in maintaining cellular energy levels in oxygen-deprived regions. Although the critical necessity of HIF1a in initiating and sustaining glycolysis in activated T cells remains under debate, 135, 138 all these studies focus on mTOR-mediated induction of HIF1a. It would be wise to consider that HIF1a is still a capital transcription factor in the response to hypoxia, a main characteristic of solid tumors, and to investigate the contribution of hypoxia-induced HIF1a on activated T cell glycolysis and clonal expansion, especially in light of the above mentioned suppressive effect of hypoxia on T cell viability and function.
In conclusion, multiple studies identify HIF1a as a key molecule in the hypoxia response by T cells. 139 On one hand, using HIF1a as target during immunotherapy might be promising by attenuating hypoxia-mediated suppression of T cell proliferation and cytolytic functions. On the other hand, however, HIF1a inhibition could shift the balance between Th cell subsets and Treg subsets, and compromise the clonal expansion of activated T cells.
Natural killer cells and natural killer T cells Natural killer (NK) cells, belonging to innate immunity, and natural killer T (NKT) cells, a subpopulation of T lymphocytes with phenotypical and functional similarities to NK cells, are unique amongst the tumor-infiltrating leukocytes, because there are no functional polarization states known to promote tumor progression. Their strong antitumor activity has been subject to many studies and is an attractive target for several innovative antitumor therapies. 140 Despite this tumor-killing potential, NK cell activity is strongly suppressed in the combined hypoxic and acidic tumor microenvironment. 141 Even mild hypoxia alone appears to strongly impair NK cell activation and cytotoxicity. 142 Unfortunately, these findings are all based on in vitro studies, and molecular mechanisms are lacking. NKT cells, on the other hand, unexpectedly, appear preferentially in the hypoxic regions of neuroblastomas. This intratumoral localization is caused by hypoxia-induced upregulation of TAM-mediated CCL20 secretion. Once the NKT cells are trapped in the hypoxic region, low-oxygen concentrations drastically impair their viability and function. Interestingly, the authors showed that NKT cells could be protected from the suppressive effects of hypoxia by cytokines, and consequently, adoptive transfer of NKT cells, engineered to express IL15, greatly improved antitumor activity. 143 However, it remains unclear which are the exact molecular mechanisms of hypoxia-mediated NKT cell suppression and whether these findings can be extrapolated to innate NK cells, and thus improve NK cell adoptive transfer efficiency.
PLATELETS
Platelets and cancer progression are tightly linked. Indeed, thrombosis and coagulation abnormalities are common phenomena in cancer patients, mainly when the tumor has progressed to the metastatic stage. 144 The discovery that platelet granules contain high amounts of VEGF 145 and other angiogenic factors shed light on the functional mechanism that could explain the link between platelets and tumor invasiveness. However, platelet granules contain both pro-and antiangiogenic factors localized in different alpha granules. The differential release, determining the final pro or antiangiogenic role of platelets, is governed by the tissue microenvironment. 146 In this context, intratumoral hypoxia has an important role, triggering the specific release of growth factors and chemokines by platelets (Figure 3 ). Despite the molecular mechanism has not been described, platelets in hypoxia can promote the recruitment of pro-angiogenic bone marrow-derived cells through the release of alpha granules containing tumor-derived factors, such as VEGF, granulocyte colony-stimulating factor, macrophage colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and matrix metallopeptidase 9. 147 However, platelets that are deficient for the antiangiogenic factor TSP-1 display a strong pro-angiogenic phenotype in the earliest stages of tumor growth, suggesting that platelets can initially inhibit angiogenesis and switch their phenotype during tumor progression. 148 Likely, intratumoral hypoxia might govern the switch from anti-to pro-angiogenic granule release by inducing differential expression of platelet receptors and activatory signals.
Proteome plasticity of platelets induced by the tumor microenvironment is a very early event during the course of the disease. The alterations of the platelet angiogenic proteome reflect the presence of microscopic tumors in mice months before these tumors can be detected by conventional methods. 149 Thus, tumorassociated alterations of platelet granule contents could be valuable biomarkers for cancer progression. Of note, treatment with antithrombotic drugs reduced metastasis in mice and improved survival of metastatic patients in some cases. [150] [151] [152] [153] However, these results need to be taken with care, as generic platelet inhibition might induce severe bleeding and alter their physiological role within the organism. Proteome or genome studies on the relevance of hypoxia in modulating platelet functions could reveal potential biomarkers that allow specific target of pro-angiogenic and pro-tumoral platelets.
CONCLUSIVE REMARKS
Cancer cells undergo genetic and epigenetic changes that allow them to escape pharmacological treatments. Thus, the initial belief was that the tumor stroma could offer novel and alternative strategies for efficacious targeted therapy because of its unchangeable and steady nature. This concept has been, however, challenged by the disappointing results of clinical trials aiming to test the value of antistroma therapies, including antiangiogenic drugs, immunotherapies, antithrombotic treatments and anti-CAF approaches. The reason underlying this failure can be ascribed to the fact that tumor stroma does change during cancer progression, and one of the environmental factors that molds the biology of stromal components is surely represented by low-oxygen tension within all kinds of tumors. To add to the complexity, hypoxia can elicit very complex and sometimes opposing responses in cancer cells and in the different stromal tumor components; therefore, a complete overview of the effects of hypoxia in the tumor is needed, in order to identify the best targets for tumor treatment. On one hand, the cellular machinery might provide instructive signals that dictate cell-fate decisions on other cells; on the other hand, it might generate permissive signals unleashing responses that are inherently defined in the protein repertoire of the cell itself. Future work will unravel the molecular mechanisms conferring specificity to the hypoxia response in different cell types.
